[1]McDermott U,Sharma SV,Dowell L,et al.Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling[J].USA:Proc Natl Acad Sci,2007,104:19936-19941.
[2]Llovet JM,Ricci S,Mazzaferro V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359:378-390.
[3]Cheng AL,Guan Z,Chen Z,et al.Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status:subset analyses of the phase III Sorafenib[J].Eur J Cancer,2012,48:1452-1465.
[4]Jelic S,Sotiropoulos GC.Hepatocellular carcinoma:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2010,21(Suppl5):v59-64.
[5]Theysohn JM,Schlaak JF,Müller S,et al.Selective internal radiation therapy of hepatocellular carcinoma:Potential hepatopulmonary shunt reduction after sorafenib administration[J].J Vasc Interv Radiol,2012,23:949-952.
[6]Richly H,Schultheis B,Adamietz IA,et al.Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma:Results from a phase I extension trial[J].Eur J Can,2009,45:579-587.
[7]Ghassan K,Abou-Alfa,Donna Niedzwieski,et al.Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC):CALGB 80802 (Alliance) [J].J Clin Oncol,2016,1:21-23.
[8]Zhang YF,Wei W,Wang JH,et al.Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus[J].Onco Targets and Therapy,2016,9:4239-4246.
[9]Wilhelm SM,Dumas J,Adnane L,et al.Regorafenib(BAY 73-4506):a new oral multikinase inhibitor of angiogenic,stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity[J].Int J Cancer,2011,129(1):245-255.
[10]Bruix J,Tak WY,Gasbarrini A,et al.Regorafenib as econdline therapy for intermediate or advanced hepatocellular carcinoma:Multicentre,open-label,phase Ⅱ safety study[J].Eur J Cancer,2013,49(16):3412-3419.
[11]Bruix J,Merle P,Granito A,et al.Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib:results of the international,randomized phase 3 RESORCE trial[J].Ann Oncol,2016,27:140-141.
[12]Yeung KT,Cohen EE.Lenvatinib in advanced,radioactive iodine-refractory,differentiated thyroid carcinoma[J].Clin Cancer Res,2015,21:5420-5426.
[13]Chuma M,Terashita K,Sakamoto N.New molecularly targeted therapies against advanced hepatocellular carcinoma:from molecular pathogenesis to clinical trials and future directions[J].Hepatol Res,2015,45:E1-E11.
[14]Oikonomopoulos G,Aravind P,Sarker D.Lenvatinib:apotential breakthrough in advanced hepatocellular carcinoma [J]?Future Oncol,2016,12:465-476.
[15]Akanay-Diesel S,Hoff NP,Kürle S,et al.Sunitinib induced pyoderma gangrenosum-like ulcerations[J].Eur J Med Res,2011,16:491-494.
[16]Cheng AL,Kang YK,Lin DY,et al.Sunitinib versus sorafenib in advanced epatocellular cancer:Results of a randomized phase III trial[J].J Clin Oncol,2013,31:4067-4075.
[17]Bhide RS,Cai ZW,Zhang YZ,et al.Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol(BMS-540215),an in vivo active potent VEGFR-2 inhibitor[J].J Med Chem,2006,49:2143-2146.
[18]Park JW,Finn RS,Kim JS,et al.Phase II,open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma[J].Clin Cancer Res,2011,17:1973-1983.
[19]Johnson PJ,Qin S,Park JW,et al.Brivanib vs sorafenib as first-line therapy in patients with unresectable,advanced hepatocellular carcinoma:results from the randomized hase III BRISK-FL study[J].J Clin Oncol,2013,31:3517-3524.
[20]Llovet JM,Decaens T,Raoul JL,et al.Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed:results from the randomized phase III BRISK-PS study[J].J Clin Oncol,2013,31:3509-3516.
[21]Sciarrino E,Simonetti RG,Le Moli S,et al.Adriamycin treatment for hepatocellular carcinoma.Experience with 109 patients[J].Cancer,1985,56:2751-2755.
[22]Lai CL,Wu PC,Chan GC,et al.Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma.A prospective randomized trial[J].Cancer,1988,62:479-483.
[23]Fuchs CS,Clark JW,Ryan DP,et al.A phase II trial of gemcitabine in atients with advanced hepatocellular carcinoma[J].Cancer,2002,94:3186-3191.
[24]Patt YZ,Hassan MM,Aguayo A,et al.Oral capecitabine for the reatment of epatocellular carcinoma,cholangiocarcinoma,and gallbladder carcinoma[J].Cancer,2004,101:578-586.
[25]Qin S,Bai Y,Lim HY,et al.Randomized,multicenter,open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J].J Clin Oncol,2013,31:3501-3508.
[26]Leung TW,Patt YZ,Lau WY,et al.Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma[J].Clin Cancer Res,1999,5:1676-1681.
[27]Wang J,He XD,Yao N,et al.A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma[J].Can J Gastroenterol,2013,27:351-363.
[28]Giraudo L,Gammaitoni L,Cangemi M,et al.Cytokine-induced killer cells as immunotherapy for solid tumors:current evidences and perspectives[J].Immunotherapy,2015,7:999-1010.
[29]Wei F,Rong XX,Xie RY,et al.Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition[J].Oncotarget,2015,6:35023-35039.
[30]Li X,Dai D,Song X,et al.A meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinoma[J].Clin Res Hepatol Gastroenterol,2014,38:583-591.
[31]Lee JH,Lim YS,Yeon JE,et al.Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J].Gastroenterology,2015,148:1383-1391.
[32]Chew V,Chen J,Lee D,et al.Chemokine-driven lymphocyte infiltration:an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma[J].Gut,2012,6:427-438.
[33]Ishiyama K,Ohdan H,Ohira M,et al.Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans[J].Hepatology,2006,43:362-372.
[34]Wu Y,Kuang DM,Pan WD,et al.Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions[J].Hepatology,2013,57:1107-1016.
[35]Wu J,Lanier LL.Natural killer cells and cancer[J].Adv Cancer Res,2003,90:127-156.
[36]Fu B,Tian Z,Wei H.Subsets of human natural killer cells and their regulatory effects[J].Immunology,2014,141:483-489.
[37]Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy [J].Nat Rev Cancer,2012,12(4):252-264.
[38]Anthony B,El-Khoueiry.Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC)[R].ASCO,2013:CA209-240.
[39]Topalian SL,Hodi FS,Brahmer JR,et al.Safety,activity,and immune correlates of anti-PD-1 antibody in cancer[J].N Engl J Med,2012,366(26):2443-2454.
[40]Herbst RS,Soria JC,Kowanetz M,et al.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients [J].Nature,2014,515(7528):563-567.